Based on the expression of estrogen receptor (ER), progesterone receptor (PgR), and ERBB2 (HER2), breast tumors are classified as luminal A, luminal B, HER2, and basal-like or triple-negative (TNBC), which exhibit different tumor aggressiveness and response to therapy [2–4]. This evidence concerns the gene ESR1 and neoplasm.